Tags

Type your tag names separated by a space and hit enter

Programmed cell death-ligand 1 (PD-L1) expression and fibroblast growth factor receptor 1 (FGFR1) amplification in stage III/IV lung squamous cell carcinoma (SQC).
Thorac Cancer. 2017 03; 8(2):73-79.TC

Abstract

BACKGROUND

This study was conducted to explore programmed cell death-ligand-1 (PD-L1) expression and fibroblast growth factor receptor 1 (FGFR1) amplification in stage IIIB/IV lung squamous cell carcinoma (SQC). Correlations between PD-L1 and FGFR1, and with clinicopathological characteristics, efficacy of platinum-based chemotherapy, and prognosis were analyzed.

METHODS

One hundred and twenty-eight consecutive stage III/IV SQC patients were enrolled in this study from 2009 to 2014. Seventy-eight patients received platinum-based chemotherapy. Immunohistochemistry was used to assess PD-L1 expression and fluorescence in situ hybridization was applied to detect FGFR1 amplification.

RESULTS

PD-L1 expression was detected in 61.7% (79/128) of lung SQC patients. Smokers had significantly higher PD-L1 expression rates than non-smokers (66.1% vs. 44.0%, P = 0.042, respectively). The objective response and disease control rates for platinum-based chemotherapy were not significantly different between PD-L1 negative and positive patients (43.3% vs. 36.2%, P = 0.434; 80.0% vs. 78.7% P = 0.840, respectively); however, overall survival in PD-L1-negative patients was significantly longer than in PD-L1-positive patients (41.5 vs. 19.3 months, P = 0.001). Twenty-five percent (32/128) of patients displayed FGFR1 amplification, with a lower rate in stage III patients compared to stage IV (17.1% vs. 36.5%, P = 0.013, respectively). There was no significant difference in FGFR1 amplification levels between overall response, disease control or overall survival rates. No correlation was observed between PD-L1 expression and FGFR1 amplification (P = 0.916).

CONCLUSION

PD-L1 expression may function as a prognostic factor in Chinese stage III/IV SQC patients. FGFR1 amplification is more prevalent in late stage SQC patients but does not predict chemotherapy response. There is no apparent correlation between PD-L1 expression and FGFR1 amplification.

Authors+Show Affiliations

Respiratory Department Division One, Shanxi Province Tumor Hospital, Taiyuan, China.Department of Thoracic Medical Oncology, The Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Beijing Cancer Hospital, Beijing Institute of Cancer Research, Beijing, China.Department of Thoracic Medical Oncology, The Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Beijing Cancer Hospital, Beijing Institute of Cancer Research, Beijing, China.Department of Thoracic Medical Oncology, The Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Beijing Cancer Hospital, Beijing Institute of Cancer Research, Beijing, China.Department of Thoracic Medical Oncology, The Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Beijing Cancer Hospital, Beijing Institute of Cancer Research, Beijing, China.Department of Thoracic Medical Oncology, The Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Beijing Cancer Hospital, Beijing Institute of Cancer Research, Beijing, China.Department of Thoracic Medical Oncology, The Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Beijing Cancer Hospital, Beijing Institute of Cancer Research, Beijing, China.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

28008744

Citation

Guo, Qinxiang, et al. "Programmed Cell Death-ligand 1 (PD-L1) Expression and Fibroblast Growth Factor Receptor 1 (FGFR1) Amplification in Stage III/IV Lung Squamous Cell Carcinoma (SQC)." Thoracic Cancer, vol. 8, no. 2, 2017, pp. 73-79.
Guo Q, Sun Y, Yu S, et al. Programmed cell death-ligand 1 (PD-L1) expression and fibroblast growth factor receptor 1 (FGFR1) amplification in stage III/IV lung squamous cell carcinoma (SQC). Thorac Cancer. 2017;8(2):73-79.
Guo, Q., Sun, Y., Yu, S., Bai, H., Zhao, J., Zhuo, M., & Wang, J. (2017). Programmed cell death-ligand 1 (PD-L1) expression and fibroblast growth factor receptor 1 (FGFR1) amplification in stage III/IV lung squamous cell carcinoma (SQC). Thoracic Cancer, 8(2), 73-79. https://doi.org/10.1111/1759-7714.12399
Guo Q, et al. Programmed Cell Death-ligand 1 (PD-L1) Expression and Fibroblast Growth Factor Receptor 1 (FGFR1) Amplification in Stage III/IV Lung Squamous Cell Carcinoma (SQC). Thorac Cancer. 2017;8(2):73-79. PubMed PMID: 28008744.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Programmed cell death-ligand 1 (PD-L1) expression and fibroblast growth factor receptor 1 (FGFR1) amplification in stage III/IV lung squamous cell carcinoma (SQC). AU - Guo,Qinxiang, AU - Sun,Yu, AU - Yu,Sifan, AU - Bai,Hua, AU - Zhao,Jun, AU - Zhuo,Minglei, AU - Wang,Jie, Y1 - 2016/12/23/ PY - 2016/01/04/received PY - 2016/09/20/revised PY - 2016/09/21/accepted PY - 2016/12/23/pubmed PY - 2017/10/31/medline PY - 2016/12/24/entrez KW - FGFR1 amplification KW - PD-L1 expression KW - squamous lung carcinoma SP - 73 EP - 79 JF - Thoracic cancer JO - Thorac Cancer VL - 8 IS - 2 N2 - BACKGROUND: This study was conducted to explore programmed cell death-ligand-1 (PD-L1) expression and fibroblast growth factor receptor 1 (FGFR1) amplification in stage IIIB/IV lung squamous cell carcinoma (SQC). Correlations between PD-L1 and FGFR1, and with clinicopathological characteristics, efficacy of platinum-based chemotherapy, and prognosis were analyzed. METHODS: One hundred and twenty-eight consecutive stage III/IV SQC patients were enrolled in this study from 2009 to 2014. Seventy-eight patients received platinum-based chemotherapy. Immunohistochemistry was used to assess PD-L1 expression and fluorescence in situ hybridization was applied to detect FGFR1 amplification. RESULTS: PD-L1 expression was detected in 61.7% (79/128) of lung SQC patients. Smokers had significantly higher PD-L1 expression rates than non-smokers (66.1% vs. 44.0%, P = 0.042, respectively). The objective response and disease control rates for platinum-based chemotherapy were not significantly different between PD-L1 negative and positive patients (43.3% vs. 36.2%, P = 0.434; 80.0% vs. 78.7% P = 0.840, respectively); however, overall survival in PD-L1-negative patients was significantly longer than in PD-L1-positive patients (41.5 vs. 19.3 months, P = 0.001). Twenty-five percent (32/128) of patients displayed FGFR1 amplification, with a lower rate in stage III patients compared to stage IV (17.1% vs. 36.5%, P = 0.013, respectively). There was no significant difference in FGFR1 amplification levels between overall response, disease control or overall survival rates. No correlation was observed between PD-L1 expression and FGFR1 amplification (P = 0.916). CONCLUSION: PD-L1 expression may function as a prognostic factor in Chinese stage III/IV SQC patients. FGFR1 amplification is more prevalent in late stage SQC patients but does not predict chemotherapy response. There is no apparent correlation between PD-L1 expression and FGFR1 amplification. SN - 1759-7714 UR - https://www.unboundmedicine.com/medline/citation/28008744/Programmed_cell_death_ligand_1__PD_L1__expression_and_fibroblast_growth_factor_receptor_1__FGFR1__amplification_in_stage_III/IV_lung_squamous_cell_carcinoma__SQC__ L2 - https://doi.org/10.1111/1759-7714.12399 DB - PRIME DP - Unbound Medicine ER -